Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 6Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Stomach Neoplasms 2Neoplasm Metastasis 2Melanoma 2Head and Neck Neoplasms 2Disease 2Colonic Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Vasculitis 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Osteomyelitis 1Nose Neoplasms 1Myelodysplastic Syndromes 1Multiple Pulmonary Nodules 1

Interventions

Cyclophosphamide 66Rituximab 43fludarabine phosphate 37Methotrexate 36Whole-Body Irradiation 34Peripheral Blood Stem Cell Transplantation 34Vincristine 33Etoposide 32Cytarabine 29Mycophenolic Acid 28Tacrolimus 23Busulfan 23Prednisone 22Doxorubicin 22Filgrastim 21merphos 20Dexamethasone 20Cyclosporine 19Melphalan 18Calcium Dobesilate 18Granulocyte Colony-Stimulating Factor 17Antilymphocyte Serum 17Radiotherapy 16Leucovorin 15dexamethasone acetate 14dexamethasone 21-phosphate 14auricularum 13prednylidene 12deltacortene 12azathiopurine 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Burkitt Lymphoma × Positron-Emission Tomography × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡